Enanta Pharmaceuticals (ENTA) Getting Somewhat Positive Media Coverage, Report Shows

News articles about Enanta Pharmaceuticals (NASDAQ:ENTA) have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Enanta Pharmaceuticals earned a news impact score of 0.16 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 47.2521289174732 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Enanta Pharmaceuticals (NASDAQ ENTA) opened at $67.32 on Friday. The stock has a market cap of $1,287.56, a P/E ratio of 76.50 and a beta of 0.64. Enanta Pharmaceuticals has a 52-week low of $25.92 and a 52-week high of $67.41.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, November 20th. The biotechnology company reported $1.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.13 by ($0.27). The company had revenue of $75.93 million during the quarter, compared to analysts’ expectations of $73.80 million. Enanta Pharmaceuticals had a return on equity of 6.46% and a net margin of 17.23%. Enanta Pharmaceuticals’s revenue for the quarter was up 491.3% compared to the same quarter last year. During the same period last year, the company earned ($0.09) earnings per share. sell-side analysts anticipate that Enanta Pharmaceuticals will post -1.57 EPS for the current fiscal year.

ENTA has been the subject of a number of research analyst reports. TheStreet raised shares of Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Wednesday, December 13th. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. Royal Bank of Canada increased their price target on shares of Enanta Pharmaceuticals from $54.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 21st. Finally, JMP Securities increased their price target on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a research report on Wednesday, October 4th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $45.25.

WARNING: “Enanta Pharmaceuticals (ENTA) Getting Somewhat Positive Media Coverage, Report Shows” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/21/enanta-pharmaceuticals-enta-getting-somewhat-positive-media-coverage-report-shows.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Insider Buying and Selling by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply